|Circadian Technologies Limited|
650 Chapel Street
Australia - Map
Phone: 61 3 9826 0399
Fax: 61 3 9824 0083
Circadian Technologies Limited develops and commercializes therapies primarily for eye disease in Australia. Its development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and R3 targets, which are used for the treatment of diseases associated with angiogenesis and lymphangiogenesis. The companys lead molecule includes OPT-302, a soluble form of VEGFR-3 that is used for treatment of wet age-related macular degeneration and blindness in the western world in people aged over 55 years. Its product pipeline also comprises VGX-100, a monoclonal antibody for VEGF-C that has completed Phase IA/IB clinical study in advanced cancer patients; and IMC-3C5, an antibody targeting VEGFR-3. In addition, the company develops CUPGUIDE, a diagnostic test, which is used in the treatment of cancers of unknown primary; and insulin through DiMiTech platform for the treatment of diabetes. Circadian Technologies Limited is based in South Yarra, Australia.
|Ms. Dominique Gayle Fisher BA (Hons), MAICD,
Non-Exec. Chairman, Chairman of Remuneration Committee and Member of Audit & Risk Committee
|Ms. Megan Baldwin Ph.D., MAICD,
Chief Exec. Officer, Managing Director and Director
|Mr. Michael Tonroe Bsc(Hons) Aca Maicd,
Chief Financial Officer and Company Sec.
|Mr. Richard Chadwick Ph.D.,
Head of Intellectual Property
|Mr. Michael Gerometta Ph.D.,
Head of CMC Devel.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in AUD.|